JP2015512914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512914A5 JP2015512914A5 JP2015503334A JP2015503334A JP2015512914A5 JP 2015512914 A5 JP2015512914 A5 JP 2015512914A5 JP 2015503334 A JP2015503334 A JP 2015503334A JP 2015503334 A JP2015503334 A JP 2015503334A JP 2015512914 A5 JP2015512914 A5 JP 2015512914A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fusion protein
- agent according
- therapeutic agents
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617370P | 2012-03-29 | 2012-03-29 | |
| US61/617,370 | 2012-03-29 | ||
| PCT/US2013/032269 WO2013148337A1 (en) | 2012-03-29 | 2013-03-15 | Methods for treating neoplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126173A Division JP2018172414A (ja) | 2012-03-29 | 2018-07-02 | 新生物を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512914A JP2015512914A (ja) | 2015-04-30 |
| JP2015512914A5 true JP2015512914A5 (enExample) | 2016-03-17 |
| JP6639228B2 JP6639228B2 (ja) | 2020-02-05 |
Family
ID=49261086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503334A Active JP6639228B2 (ja) | 2012-03-29 | 2013-03-15 | 新生物を治療するための方法 |
| JP2018126173A Pending JP2018172414A (ja) | 2012-03-29 | 2018-07-02 | 新生物を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126173A Pending JP2018172414A (ja) | 2012-03-29 | 2018-07-02 | 新生物を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150216937A1 (enExample) |
| EP (1) | EP2830648A4 (enExample) |
| JP (2) | JP6639228B2 (enExample) |
| KR (2) | KR20150002706A (enExample) |
| CN (2) | CN104470535A (enExample) |
| AU (2) | AU2013240191B2 (enExample) |
| CA (1) | CA2868431A1 (enExample) |
| WO (1) | WO2013148337A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150250717A1 (en) | 2014-03-06 | 2015-09-10 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
| EP3233192B1 (en) | 2014-12-15 | 2021-04-14 | Washington University | Compositions and methods for targeted cytokine delivery |
| US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| AU2017213659B2 (en) | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
| PE20231050A1 (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| CN118453872A (zh) * | 2016-05-06 | 2024-08-09 | 塔里斯生物医药公司 | 治疗下尿路尿道上皮癌的方法 |
| DK3523416T3 (da) * | 2016-10-05 | 2025-03-03 | Univ Central Florida Res Found Inc | Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US11046768B2 (en) * | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| SG10201913998YA (en) | 2017-07-25 | 2020-03-30 | Taris Biomedical Llc | Methods of treating tumor metastasis |
| IL302714B1 (en) | 2017-11-08 | 2026-01-01 | Taris Biomedical Llc | Methods for treating and maintaining bladder cancer using gemcitabine |
| CN108392634A (zh) * | 2018-03-28 | 2018-08-14 | 清华大学 | B7s1抑制剂在制备肝癌药物中的用途 |
| US12325734B2 (en) | 2019-01-15 | 2025-06-10 | Altor Bioscience Llc | Human immunodeficiency virus-specific T cell receptors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537973B1 (en) * | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US20050036951A1 (en) * | 2003-01-09 | 2005-02-17 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
| UA101945C2 (uk) * | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| EP1842553A1 (en) * | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| US20120282245A1 (en) * | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| US20110070191A1 (en) * | 2008-03-19 | 2011-03-24 | Wong Hing C | T cell receptor fusions and conjugates and methods of use there of |
| WO2011066379A2 (en) * | 2009-11-24 | 2011-06-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION |
-
2013
- 2013-03-15 JP JP2015503334A patent/JP6639228B2/ja active Active
- 2013-03-15 KR KR20147030163A patent/KR20150002706A/ko not_active Ceased
- 2013-03-15 CA CA2868431A patent/CA2868431A1/en not_active Abandoned
- 2013-03-15 US US14/388,575 patent/US20150216937A1/en not_active Abandoned
- 2013-03-15 KR KR1020197034966A patent/KR20190134832A/ko not_active Ceased
- 2013-03-15 WO PCT/US2013/032269 patent/WO2013148337A1/en not_active Ceased
- 2013-03-15 AU AU2013240191A patent/AU2013240191B2/en active Active
- 2013-03-15 CN CN201380028390.7A patent/CN104470535A/zh active Pending
- 2013-03-15 EP EP13768152.4A patent/EP2830648A4/en not_active Ceased
- 2013-03-15 CN CN202010255455.3A patent/CN111420032A/zh active Pending
-
2018
- 2018-05-22 AU AU2018203584A patent/AU2018203584A1/en not_active Abandoned
- 2018-07-02 JP JP2018126173A patent/JP2018172414A/ja active Pending
-
2019
- 2019-07-12 US US16/510,835 patent/US20190328838A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512914A5 (enExample) | ||
| Helm | The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer | |
| HRP20171153T1 (hr) | Protutijela protiv csf-1r | |
| FI4241849T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2009286795A5 (enExample) | ||
| IL276434B2 (en) | Combination therapy involving antibodies against claudin 18.2 for the treatment of cancer | |
| JP2011515481A5 (enExample) | ||
| JP2016514689A5 (enExample) | ||
| JP2013529183A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| ES2684950T3 (es) | Usos de inmunoconjugados dirigidos a CD138 | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2019517512A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2020142534A (ru) | Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство | |
| JP2008537778A5 (enExample) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2014530215A5 (enExample) | ||
| NZ610851A (en) | Compounds and compositions for the treatment of cancer | |
| MX2013000779A (es) | Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales. | |
| RU2012102415A (ru) | Способ лечения рака антагонистом dll4 и химиотерапевтическим средством | |
| RU2018138976A (ru) | Лечение рака головного мозга | |
| JP2013540489A5 (enExample) | ||
| JP2013523843A5 (enExample) |